日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.

在健康受试者中,阿达木单抗生物类似药(M923)与阿达木单抗(Humira)具有药代动力学等效性、可比安全性和免疫原性

Hillson Jan, Mant Tim, Rosano Molly, Huntenburg Carolyn, Alai-Safar Mehrshid, Darne Siddhesh, Palmer Donna, Pavlova Borislava G, Doralt Jennifer, Reeve Russell, Goel Niti, Weilert Doris, Rhyne Paul W, Chance Kamali, Caminis John, Roach James, Ganguly Tanmoy

Biosimilars in rheumatology: understanding the rigor of their development

风湿病学中的生物类似药:了解其研发的严谨性

Goel, Niti; Chance, Kamali